BlossomHill Therapeutics Inc. (BLSM)
NASDAQ: BLSMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
BLSM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $461.20M
- EPS (TTM)
- -$10.38
- Dividend yield
- None
- 52-week range
- 11.02 – 27.99
- Day range
- 13.90 – 15.63
- Volume / Avg
- 270.74K / 193.15K
- Beta
- —
- Shares outstanding
- 31.78M
52-week range
BLSM stock today
On Nov 20, BLSM ended the session at $14.51, adding $0.10 (0.69%), versus the S&P 500's 3.70% decline. At this level, BLSM sits in the middle of its 52-week range of $11.02 to $27.99: 48.2% below the high, set on Sep 21, 2026 and 31.7% above the low. BlossomHill Therapeutics has posted a net loss over the last twelve months (EPS of -$10.38), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About BlossomHill Therapeutics
Company profileBlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jingrong Jean Cui Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 69
- IPO year
- 2026
- Website
- bhtherapeutics.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$35.40+143.97%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.29 vs $-0.93
- Surprise
- -38.71%
BLSM news
All BLSM news- BlossomHill Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswire
- BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung CancerGlobeNewswire
- Biotech Stocks At 52-Week Highs - BLSM +18% On Positive Trial Data, ADPT, ILMN, CBLL, NEOGNasdaqADPT, BLSM, CBLL, ILMN
- Biotech Stocks At 52-Week Highs - PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTHNasdaqATRC, BLSM, FTH, PHVS
- Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADLNasdaqBLSM, CADL, NEO, ORMP
BlossomHill Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs BLSM |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs BLSM |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs BLSM |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs BLSM |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs BLSM |
| MNPRMonopar Therapeutics Inc. | 69.00 | -1.84% | $467.60M | vs BLSM |
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs BLSM |
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs BLSM |
Indexes, lists and sector
BlossomHill Therapeutics stock FAQ
What is BlossomHill Therapeutics's stock price today?
BLSM last traded at $14.51 as of Nov 20, 4:00 PM EST, up 0.69% on the day. Prices are delayed at least 15 minutes.
Who is BlossomHill Therapeutics's CEO?
Dr. Jingrong Jean Cui Ph.D. is the chief executive officer of BlossomHill Therapeutics Inc., which has about 69 employees.
What is the BLSM 52-week high?
The 52-week high for BLSM is $27.99 and the 52-week low is $11.02. The stock is currently 48.2% below its high.